Early detection and prediction of cardiotoxicity after radiation therapy for breast cancer: the BACCARAT prospective cohort study by Sophie Jacob et al.
Jacob et al. Radiation Oncology  (2016) 11:54 
DOI 10.1186/s13014-016-0627-5STUDY PROTOCOL Open AccessEarly detection and prediction of
cardiotoxicity after radiation therapy for
breast cancer: the BACCARAT prospective
cohort study
Sophie Jacob1*, Atul Pathak2, Denis Franck3, Igor Latorzeff3, Gaelle Jimenez3, Olivier Fondard4, Matthieu Lapeyre5,
Daniel Colombier5, Eric Bruguiere5, Olivier Lairez6, Benoit Fontenel7, Fabien Milliat8, Radia Tamarat9,
David Broggio10, Sylvie Derreumaux11, Marianne Ducassou3, Jean Ferrières12, Dominique Laurier1,
Marc Benderitter13 and Marie-Odile Bernier1Abstract
Background: Radiotherapy (RT) for breast cancer presents a benefit in terms of reducing local recurrence and deaths
resulting from breast cancer but it can lead to secondary effects due to the presence of neighboring cardiac normal
tissues within the irradiation field. Breast RT has been shown to be associated with long-term increased risk of heart
failure, coronary artery disease, myocardial infarction and finally cardiovascular death more than 10 years after RT.
However, there is still a lack of knowledge for early cardiotoxicity induced by breast RT that can appear long before the
onset of clinically significant cardiac events. Based on a 2-year follow-up prospective cohort of patients treated with
breast RT, the BACCARAT (BreAst Cancer and CArdiotoxicity Induced by RAdioTherapy) study aims to enhance
knowledge on detection and prediction of early subclinical cardiac dysfunction and lesions induced by breast RT and
on biological mechanisms potentially involved, based on functional and anatomical cardiac imaging combined with
simultaneous assessment of multiple circulating biomarkers and accurate heart dosimetry.
Methods/Design: BACCARAT study consists in a monocentric prospective cohort study that will finally include 120
women treated with adjuvant 3D CRT for breast cancer, and followed for 2 years after RT. Women aged 50 to 70 years,
treated for breast cancer and for whom adjuvant 3D CRT is indicated, without chemotherapy are eligible for the study.
Baseline (before RT) and follow-up data include measurements of functional myocardial dysfunction including strain and
strain rate based on 2D-speckle tracking echocardiography, anatomical coronary lesions including description of plaques
in segments of coronary arteries based on Coronary computed tomography angiography, and a wide panel of circulating
biomarkers. The absorbed dose is evaluated for the whole heart and its substructures, in particular the coronary arteries.
Analysis on occurrence and evolution of subclinical cardiac lesions and biomarkers will be performed and completed with
dose-response relationship. Multivariate model of normal tissue complication probability (NTCP) will also be proposed.
Discussion: Tools and results developed in the BACCARAT study should allow improving prediction and prevention of
potential lesions to cardiac normal tissues surrounding tumors and ultimately enhance patients’ care and quality of life.
Trial registration: ClinicalTrials.gov: NCT02605512
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It has been shown that adjuvant Radiotherapy (RT) for
breast cancer presents a benefit in terms of reducing
local recurrence and deaths resulting from breast cancer
[1]. However, breast RT can lead to secondary effects
due to the presence of neighboring normal tissues within
the irradiation field, including the heart. The severity of
radiation-induced toxicity to healthy tissues can unfortu-
nately affect the quality of life of cancer survivors.
Long term cardiac events
Breast cancer RT irradiation of the heart has been
shown to be associated with long-term cardiac toxicity
such as heart failure, coronary artery disease, myocardial
infarction and finally cardiovascular death more than
10 years after RT with relative risks within the range of
1.2 to 3.5 by comparing left breast treated patients (with
higher exposure to heart) to right ones or unexposed
ones [1–4]. Moreover, cardiac damage was shown to be
correlated with the heart-absorbed dose with 7.4 % rate
increase of ischemic heart disease per one Gray (95 %
confidence interval, 2.9 to 14.5; P < 0.001), with no mini-
mum threshold for risk [4]. Retrospective studies based
on records of patients treated with radiation therapy for
breast cancer who had undergone a coronary angiog-
raphy many years after RT, also showed a link between
radiation and location of stenosis as stenosis were often
present in left anterior descending artery [5–7]. These
studies revealed the importance of simultaneous consid-
eration of the location of radiation doses at the struc-
tures of the heart combined with localized effects,
particularly in the coronary arteries [8, 9]. However,
these retrospective studies only considered patients
treated until the 90’s that secondarily developed cardiac
diseases but didn’t provide information on early signs of
cardiotoxicity that can appear long before the onset of
these clinically significant cardiac events.
Subclinical cardiac changes
Long before the onset of clinically significant cardiac
events occurring many years after RT, some subclinical
cardiac changes can occur over weeks, months or first
years after RT, that can be detected either based on
functional dysfunction or anatomical modifications
measurements.
Echocardiography and myocardial changes
Cardiac echography can be used to evaluate myocardial
dysfunction. Global Longitudinal Strain and strain rate
(GLS) assessed using automated 2D-speckle-tracking
echocardiography (STE) is a recent technique for detect-
ing and quantifying subtle disturbances in Left ventricu-
lar (LV) systolic function. This technique is operator
independent, more reproducible than ejection fraction(EF) and GLS was shown to be a superior predictor of
cardiac events compared to EF. In particular, this
method was used in the context of cardiotoxicity after
breast RT. In Belgium, two prospective studies were
based on measurements of strain and strain rate as an
indicator of myocardial contractility [10, 11]. Comparing
the strain before breast radiation, then a few months
later, both studies showed significant changes related to
radiotherapy. The most recent study included 51 women
treated for left breast cancer and 24 women treated for
right breast cancer. Both strain and strain rate were
significantly decreased (mean 5 %) during the first
year following RT for left-sided patients: a decrease
in strain was observed at all post-RT time points
(−17.5 ± 1.9 % immediately after RT, −16.6 ± 1.4 % at
8 months and −17.7 ± 1.9 % at 14 months vs −19.4 ± 2.4 %
before RT, p < 0.01). Similar results for longitudinal strain
decrease were also observed in a recent German study
[12]. Based on this clinical state, it appeared that early car-
diotoxicity of radio-induced breast RT could be measured
based on subclinical myocardial functional changes which
is concordant with recent publication of recommenda-
tions in the evaluation of cardiovascular complications
after radiotherapy in adults including in particular cardiac
echography examination [13]. However these results on
strain and strain rate remain to be confirmed and more
precise analyses depending on the dose distribution over
the surface of myocardial could enable a better under-
standing of a possible dose response.
CCTA and coronary changes
Coronary computed tomography angiography (CCTA)
provides morphological information: visualization of the
coronary arteries; visualization of calcification of the cor-
onary arteries and determination of calcium score which
reflects the evolution of the coronary disease may help
to visually locate vulnerable lipid-rich soft plaques (little
or non-calcified) as potential risk of coronary occlusion.
By limiting radiation exposure to the phase of interest
(generally, the motion sparse diastolic phase), the radi-
ation dose can be reduced, with an average dose < 5 mSv
[14]. This CCTA method was used for patients treated
with radiation therapy to the chest for Hodgkin lymph-
oma that developed coronary damages after their RT
[15, 16] but even more generally in the follow-up of car-
diac patients [17]. Lehman et al. showed the potential of
CCTA for accurate monitoring of the progression of
calcified and non-calcified plaques from a population of
69 patients with chest pain examined twice at 2-year in-
tervals [17]. From tracking nearly 9000 segments of cor-
onary arteries in the cohort, a significant 12.7 % increase
in the mean number of cross-sections containing any
plaque was observed (p = 0.01). While this study did
not consider radiation exposure of the heart, it does
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short-term changes in coronary changes. No study
focused on women treated with breast radiotherapy
while CCTA has a potential to detect the onset or
progression of early coronary changes due to
irradiation.
Circulating biomarkers
From a biological point a view, understanding the
biological mechanism of the initiation and progression
of early radiotherapy side effects on normal tissue such
as cardiac tissue is also an important issue. To our
knowledge, there are no specific and early biomarkers of
radiation-induced heart damage at the present time. Ac-
cording to the dose distributions at heart, ionizing radi-
ation can generate cardiac injury and a major challenge
remains the identification of reliable biomarkers that
could help to diagnose and predict cardiotoxicity. De-
pending on the type of injuries (microvascular rarefac-
tions, coronary damage, tissue inflammation) potentially
relevant biomarkers are different.
Many classical biomarkers (C-reactive protein, N-
terminal pro-B–type natriuretic peptide (NT-proBNP)
and troponin (TnI), …) were shown to be potential
biomarkers for cardiac damage, in particular after
radiotherapy [18–20]. Circulating inflammatory cyto-
kins [21] can also sign tissue inflammation. It was
also showed that irradiation induces acute endothe-
lial activation or dysfunction that can be observed
many weeks after irradiation and resulting in pro-
inflammatory endothelial phenotype.
Another hypothesis to explore is that the irradiation
may be responsible for an increase in the circulating
levels of certain miRNAs expressed by cells of the
heart tissue Currently, the potential function of extra-
cellular miRNAs is being studied intensively, and the
first studies have confirmed that miRNAs may indeed
function in cell-to-cell communication. [22]. Many
studies have reported the use of miRNAs as circulat-
ing biomarkers for diagnosis or prognosis of cardio-
vascular diseases. Although many of those studies still
require replication in multiple independent study pop-
ulations, the picture emerges that some plasma miR-
NAs are quite specific for cardiovascular pathologies
and may be useful for diagnostic and monitoring
purposes.
The complex and multifactorial nature of athero-
genesis and development of atherothrombotic compli-
cations involves numerous interactions between
various cell types inside the vascular wall (e.g., macro-
phages and smooth muscle cells) and in the blood
(e.g., leukocytes and platelets). One relatively recent
advance in this area is the discovery of circulating mi-
croparticles. High levels of circulating microparticlesfound in many cardiovascular diseases demonstrate
the importance of platelet, monocyte and endothelial
activation and could condition remote sustainability
illnesses [23].
Based on this state of art, the simultaneous assessment
of multiple biomarkers may be of strong interest for RT
cardiotoxicity.
Cardiac radiation exposure
Considering the dosimetric point of view is also import-
ant to quantify precisely the risk of cardiac lesion. As
awareness of radiotherapy cardiotoxicity has grown and
technology has developed, in the history of breast cancer
RT regimens, the range of doses to the heart has chan-
ged over the past few decades [24–26]. Mean heart dose
decreased from more than 5Gy in the 50’s to less 3 Gy
in the last decade [27] and availability of 3-dimensional
CT planning (3D CRT) in the 90’s has enabled clinicians
to reduce normal tissue doses generally.
Routinely, whole heart dose-volume histograms (DVH)
are available based on radiotherapy simulation CT scans.
However these DVH cannot provide information on the
location of higher doses. Highest cardiac radiation doses
can be observed in the apex and the apical-anterior seg-
ment and some hot spots > 50Gy persist in some parts
of the heart [12] which may still today induce cardiac le-
sions, in particular for coronaries [28]. To avoid damage
and complications to healthy tissues, dose constraints
are applied to the organs at risk. The QUANTEC -
Quantitative Analysis of Normal Tissue Effects in the
Clinic- recommendations, specify that the heart should
always be contoured and less than 10 % of the heart
must receive more than 25 Gy: "For partial irradiation, a
conservative model-based estimates predict that a
V25Gy < 10 % (in 2 Gy per fraction) will be associated
with a <1 % probability of cardiac mortality 15 years
after RT." [29]. However, no dose recommendation exists
for the coronary arteries whereas calculated mean heart
doses highly differ from mean coronary arteries doses
due to important dose gradient. In clinical practice,
coronary arteries are not contoured. The specific
relationships between doses to cardiac structures and
subsequent toxicity have not been well defined. As a
consequence, studies based on radiation dosimetry that
is able to take account of the distribution of dose within
the heart (rather than just the mean heart dose) may
provide further insight into the spatial location of heart
damages in breast cancer RT [28]. Precise approach of
heart substructure dosimetry has been developed at
IRSN for Hodgkin patients by merging RT simulation
CT scans and CCTAs to obtain detailed cardiovascular
anatomies and finally radiation treatment parameters
were used to estimate CA radiation doses [30]. Similar
approach could be used for breast cancer radiotherapy.
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The relationship between dosimetry data and toxicity to
healthy tissue is a key element in the ability to calculate
risk. Mathematical models have been developed in re-
cent years with the aim of using dosimetric data (mainly
DVH) to estimate a complication probability (mainly a
clinical sign): the NTCP models (Normal Tissue Compli-
cation Probability). Research on parameters to optimize
the NTCP models (physical, imaging, dosimetry, clinical)
are a major challenge to improve knowledge on the rela-
tionship between a received dose and toxicity to healthy
tissue [31, 32]. In addition, the enrichment with bio-
logical data of these models is a fundamental NTCP
track in the overall goal of optimizing risk prediction. In
the context of cardiotoxicity, this type of model has been
poorly exploited [33], due to the long lag time to see the
clinical signs and the fact that toxicity evaluation criteria
is limited primarily to acute effects, but rarely to the late
effects that develop after several years. By defining a
short term subclinical cardiotoxicity, it would neverthe-
less be possible to apply these methods to know predic-
tors of subclinical complications and ultimately to
predict the risk of subclinical complication itself predict-
ive of clinically significant complication that would




Based on a 2-year follow-up prospective cohort of
patients treated with breast radiotherapy (3D CRT),
the BACCARAT study aims to enhance knowledge on
detection and prediction of early subclinical cardiac
dysfunction and lesions induced by breast cancer radio-
therapy and on biological mechanisms potentially involved,
based on functional and anatomical cardiac imaging com-
bined with simultaneous assessment of multiple circulating
biomarkers and accurate heart dosimetry.
The primary objective is:
I. To evaluate the occurrence and evolution of
subclinical cardiac lesions at myocardial levels
(measure of myocardial contractility - strain) and
coronary levels (measure of coronary plaque index)
based on cardiac imaging techniques (cardiac
ultrasound exam"2D strain" and CCTA).
The secondary objectives are:
II. Study of the temporal variations of a panel of
targeted circulating biomarkers of microvascular
rarefactions, coronary damage, and tissue
inflammation related with breast RT.III. Evaluate precisely the absorbed doses, for the whole
heart and for the different structures of the heart,
specifically the coronary arteries.
IV. Analyse the dose-response relationship between
subclinical cardiac changes, biomarkers, and
absorbed doses and propose multivariate model of
normal tissue complication probability (NTCP),
which takes into account relationships among all
these parameters and potentially offer a powerful
approach to the optimization of risk assessment.
V. Establish a biobank of plasma for further analysis of
biomarkers linked to the study of RT cardiotoxicity.
Study design and population
BACCARAT study consists in a monocentric prospective
cohort study that will finally include 120 women treated
with adjuvant 3D CRT for unilateral breast cancer in the
Clinique Pasteur in Toulouse, France, without chemo-
therapy, and followed for 2 years after RT.
In the Clinique Pasteur, there are no competing
methods to 3D-CRT at the moment. All patients with
breast cancer are treated with 3D-CRT and breath-hold
gating is used for patients treated left breast cancer with
heart very close to the anterior chest wall or for dose
constraints achievement (mean heart dose < 5Gy and
V25Gy < 10 %). Women aged between 50 and 70 years,
for whom adjuvant 3D CRT is indicated with or without
breath-hold gating, with no indication of chemotherapy
are eligible for the study. Both women with left (80 % of
the sample) or right (20 % of the sample) breast cancer
are included. This choice to include both sides is justi-
fied by two reasons: (i) if the internal mammary chain is
treated significant doses can result, whatever the treated
side; (ii) if the internal mammary chain is not treated the
right side treatment will provide lower doses, an import-
ant point for the dose response analysis. With this de-
sign, each patient (after RT) could be her own control
(before RT). Moreover, the left-sided patients could also
be compared to the right-sided patients. Inclusion and
exclusion criteria are presented in Table 1.
Study procedures
The study flow chart is presented in Fig. 1. It is planned
to include the 120 women in 2 years (concordant with
the number of patients yearly treated in Clinique
Pasteur) and the end of the study is anticipated for the
end 2019.
Each patient is included at baseline before RT and
followed for 2 years post radiotherapy.
 At baseline, before RT, in addition to classical care,
patients have cardiology consultation including
description of potential cardiovascular risk factors;
2D-speckle-tracking echocardiography (see Table 2)
Table 1 Inclusion and exclusion criteria
Inclusion criteria Exclusion criteria
• Age between 50 and 70 years
• Women surgically treated for left or right breast cancer and for whom
adjuvant treatment is radiotherapy with irradiation of the breast or
chest wall irradiation and possibly ganglion chains,
• Adjuvant radiotherapy with 3D CRT performed in Clinique Pasteur Toulouse
• WHO performance status ECOG (Eastern Cooperative Oncology Group -
index usually used to describe the patient's condition) = 0 or 1
• Being volunteer to participate in the study and having signed the
consent form
• Indication of adjuvant chemotherapy
• Clinically or radiologically detectable metastasis
• Personal history of coronary artery disease or myocardial disease
• Personal history of breast cancer or other cancer requiring
radiotherapy to the thorax
• Patient with controlled infection or severe disease and/or
non-hazardous to their participation in the study
• Contraindications to injection of iodinated contrast (for CCTA):
pregnancy, renal failure, allergy
• Pregnancy, lactation
• Abnormal echocardiography before radiotherapy: - LVEF
<50 % - Longitudinal strain > − 16 % - Longitudinal strain
rate <1 %/s - Abnormal wall motion
• CCTA before radiotherapy showing that therapeutic management
is required (by decision of the radiologist and cardiologist)
3D CRT 3D conformal radiation therapy, WHO World Health Organisation, CCTA coronary computed tomography angiography, LVEF left ventricular
ejection fraction
Fig. 1 BACCARAT study flowchart
Jacob et al. Radiation Oncology  (2016) 11:54 Page 5 of 10
Table 2 Echocardiographic measurements in BACCARAT
protocol
- Left Ventricular Ejection Fraction measured using Simpson’s biplane
method
- Left ventricular end-diastolic volume measured using Simpson’s biplane
method
- Left ventricular end-systolic volume measured using Simpson’s biplane
method
- Left ventricular end-diastolic diameter measured using M-mode
- Left ventricular mass measured according to ASE/EAE guidelines
- Global and segmental longitudinal strain
- Global and segmental longitudinal strain rate
- Global and segmental radial strain rate
- Global and segmental radial strain rate
- E/A wave ratio
- E/Ea wave ratio (lateral annulus)
- TAPSE (tricuspid annular plane systolic excursion)
- Tricuspid annular S wave
- Systolic pulmonary arterial pressure (based on a measure assuming a
right atrial pressure of 5 mmHg)
- Left ventricular outflow tract diameter
- Left ventricular outflow tract velocity time integral
- Heart rate
- Cardiac output measured by multiplying heart rate by stroke volume
Bold data are major index taken into account for subclinical cardiac event
Table 3 List of circulating biomarkers measured in BACCARAT
protocol
Classical biomarkers of cardiac injury
C-reactive protein, Troponin I, B-type natriuretic peptide (NT-Pro BNP),
beta2-Microglobulin, Galectin 3
Inflammatory cytokines:
Interleukin 6, Interleukin 8, Interleukin 18, TNF-α
Endothelial activation and dysfunction
sVCAM,-1, s-ICAM-1, E-selectin, P-selectin, vWF, PAI-1, Fibrinogen,
Thrombomoduline, TGF-β1
Microparticles
CD14(monocytes), CD31(endothelial), CD41(platelets), CD3(lymphocyte),
CD235a (erythrocyte)
microRNAs
miR-1, miR-133, miR-208, miR-499, miR-126, miR-130, miR-145, miR-181,
miR-150, miR-155, miR-223, miR-17, miR-18, miR-22, miR-34, miR-92,
miR-140, miR-182, miR-199, miR-423, miR-590.
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(see Fig. 2) are performed; specific blood sample for
biomarkers analysis is collected (see the list of
biomarkers in Table 3).
 At the end of RT another specific blood sample for
biomarkers analysis is collected.Fig. 2 15 segments of coronary arteries. LM: Left main coronary artery; LAD
coronary artery. For each segment, the following index are measures: steno
(adapted from [41]) Six month after RT another specific blood sample
for biomarkers analysis is collected and 2D-speckle-
tracking echocardiography is performed.
 Two years after RT corresponding to the end of
follow-up, a last blood sample for biomarkers
analysis is collected; 2D-speckle-tracking
echocardiography and Coronary computed
tomography angiography are performed.
Study endpoints
The primary endpoint is a subclinical cardiac outcome
defined as follows: between baseline (before RT) and
2 years post RT, a decrease in the global and segmental
longitudinal strain or strain rate measured by 2D-STE of
at least 5 % and/or an increase in the number of: left anterior descending artery; LCX: left cicumflex artery; RCA: right
sis in % narrowed; presence of calcification; presence of soft plaque
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CCTA of at least 15 %. These average percentages were
chosen based on those observed in previous studies and
can be considered clinically pertinent [17, 34–37].
The secondary endpoints are:
– Decrease in the strain or strain rate between
measurements made before RT and 6 months after RT.
– Modified series of biomarkers between the
measurements before RT and: just after RT,
6 months after RT, 24 months after RT.
– Correlation between the absorbed radiation dose to
the whole heart and different structures of the heart
and measurements of strain and strain rate and
number of coronary segments containing any plaque
measured 2 years after RT.Sample size calculation
The sample size was based on a statistical power of
80 %, an alpha-risk of 5 %, the definition of the
primary endpoint (a decrease in the global and seg-
mental longitudinal strain or strain rate of at least
5 % and/or an increase in the number of coronary
segments containing any plaque of at least 15 %).
Baseline measurements were collected from previous
publications:
– Mean global longitudinal strain before RT [36]:
−16.5 % ± 2.1 %.
– Mean global longitudinal strain before RT [36]:
−1.00/s ± 0.13/s.
– Number of segments with coronary plaques [37]:
2.1 ± 1.0 segments.
Taking into account tailed test for comparisons, but
also exclusion criteria (±10 % of women whose echo-
cardiography or CCTA at baseline may be abnormal
and require therapeutic management and should be
excluded; ± 5 % of women may resort to cardiotoxic
chemotherapy during the 2 year follow-up and should
also be excluded; less than 1 % of women likely to
die within 2 years after RT - these women will be an-
alyzed until the date of death), the inclusion of 120
women is necessary.Planned analysis
A strength of the study is that each patient will her own
control (unexposed status before RT) and evaluations
will be based on individual changes of measurements
over time. Paired tests for comparisons will be used. All
tests will be bilateral with alpha = 5 %. Patients’ baseline
characteristics before RT (pre-RT) will be used as
"reference" values.(o) Description of the population at baseline (before
RT) will be performed including: the medical data
collected in the questionnaire, in particular the risk
factors for cardiovascular disease; measurements of all
biomarkers; 2D-STE measurements including strain
and strain rate; CCTA measurements including mean
number of coronary segments with plaques. Descriptive
statistics (means, standard deviations, percentages and
confidence intervals of 95 %) will be used the whole
cohort.
(i) For the analysis of primary endpoint, the occurrence
and progression of early subclinical cardiac lesions will
be analyzed based on prevalence study and Chi-square
tests.
(ii) Wilcoxon tests for paired-samples will be used to
study the variations of targeted circulating biomarkers
during follow-up. Crude temporal trends will also be
considered.
(iii) A detailed dose reconstruction will be performed
for each woman. CT images used for treatment
planning allow delineation of the heart and
surrounding organs. However, on these images the
coronary arteries are not visible and cannot be
delineated. Registration of the planning and coronary
angiography CT images will allow delineation of the
coronary arteries on the planning CT images. Using the
3D dose matrix associated with the RTDose file
generated during treatment planning [38] and the
added coronary contours, dose volume histograms and
3D dose maps [28] of the whole heart and coronaries
will be generated. This process will be performed with
the Isogray treatment planning software (http://
www.dosisoft.com/en/rt-planning/tps-isogray/dose-
calculation-models.html). A description of the doses
thus obtained will be shown for the whole cohort of
women.
(iv) Spearman correlations will provide results on the
association between measurements of strain and strain
rate and indices of coronary plaques and the
measurement of biomarkers and the radiation dose
absorbed by the different structures of the heart.
Dose-response relationship between subclinical and
dosimetric data will be studied in order to provide
results on the effect of dose on subclinical outcome.
These relationships will be established from coarse to
fine levels, considering first the heart as a whole and
going through different substructures. Logistic regression
models as well as generalized linear model and repeated
data models could be used for the study of the variation
between 0 and 2 years the intermediate measurements.
(v) For individualized risk for each patient, multivariate
model of normal tissue complication probability
(NTCP), which takes into account relationships among
all parameters will be proposed based on subclinical
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and dosimetric data using logistic regression and
forward variable selection.
Discussion
Breast RT was associated with long-term cardiac toxicity
more than 10 years after treatment with relative risks of
clinically significant cardiac events, including ischemic
heart disease, within the range of 1.2 to 3.5. In France,
ischemic heart disease is the first specific cause of death
among women and breast cancer. It is the most frequent
type of cancer among women with nearly 50,000 new
cases diagnosed each year. BACCARAT is thus posi-
tioned at a crossing point of two leading causes for
women morbidity.
Today, some residual risk of secondary effects due to
the presence of normal tissues in the irradiation field re-
mains. This can unfortunately affect the quality of life of
breast cancer survivors, who are increasingly frequent.
As a consequence, there is a need for further research to
improve early detection of late cardiac effects in mostly
asymptomatic patients, and also to improve prediction
and prevention [39].
The BACCARAT project is a multidisciplinary novel
approach to early detect radiation-induced cardiotoxicity
based on an early stage clinical study. The long term sig-
nificance of the observed changes being an important
issue, at the end of the 2-year follow up of the study,
each patient will be proposed to participate in a large
multicentric study on long term follow-up of cardiac
events with clinical follow-up going forward for 10 years
at least.
Some hypothesis will be investigated in BACCARAT:
the choice of subclinical cardiac lesions index, the super-
vised analysis of targeted biomarkers, the methodology
and clinical application for a precise heart dosimetry and
doses constraints that could be enhanced during RT, the
choice to model and possibly predict the cardiotoxicity
risk by combining biological, clinical and dosimetric
parameters.
The dosimetric work performed in BACCARAT with a
degree of precision never reached before is a strength of
the study. Effects of specific doses to the whole heart
and to specific cardiac substructures have only been
assessed in a few studies [4] [30] that revealed the
importance of better knowledge for the effects of radio-
therapy to critical structures of the heart, including the
effect of both radiation dose and volume of the heart
exposed. In particular, based on dose reconstructions
performed with patient-specific simulation CT scan and
CCTA, Moignier et al. [30] showed that use of mean
heart dose as surrogate to the coronary doses is not
reliable. This patient-specific approach was retained
for BACCARAT dosimetry. Consideration of irradiatedstructures within the heart may prove fruitful for the fu-
ture and is concordant with recommendations for future
studies based on radiation dosimetry that are able to take
into account the distribution of dose within the heart
(rather than just the mean heart dose) may provide a
better prediction of the heart diseases following breast
radiotherapy [40, 41]. Moreover, the approach of sim-
ultaneous assessment of multiple biomarkers, includ-
ing microparticules and miRNAs was never
performed before and should help to understand
some biological mechanisms involved in the radiation-
induced cardiac changes.
Provided with the patient’s own biological, clinical and
dosimetric parameters, the NTCP models should allow
an individualized risk for each patient. These new tools
and results developed in the BACCARAT project will
allow for the optimization of radiotherapy protocols
leading to personalized treatments with increased thera-
peutic efficacy. It should also improve prediction and
prevention of potential lesions to cardiac normal tissues
surrounding tumors and ultimately enhance patients’
care and quality of life.
BACCARAT project could finally enhance cardio-
oncology that has developed recently to ensure the
implementation of primary prevention strategies and
screening protocols for early recognition of cardiotoxi-
city in RT treated patients, as early administration of
advanced treatment for signs of cardiac lesions may be
crucial. By anticipating the cardiac risk after breast RT,
one could reduce the cost for patients care.
Ethics approval and consent to participate
This study has received ethical approval from the French
South West Committee for Protection of Persons (ID:
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The study is registered on clinicaltrials.gov with the
following ID: NCT02605512.
Status of the study
The study is currently recruiting patients.
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